RxDoctor Payments Data

Daeryl Williamson

Psychiatric/Mental Health · Tappahannock, VANPI 1295397123

Payments from drug & device makers

$600in general payments, 2019–2025

Across 26 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$196
  • Teva Pharmaceuticals USA, Inc.$181
  • AbbVie$47
  • Otsuka America Pharmaceutical, Inc.$44
  • Neurocrine Biosciences, Inc.$43
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$37
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$48981%
  • Education$11119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$600 in reported general payments places this provider in the 55th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$17,785
Medicare patients
58
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate84$297,914
IngrezzaValbenazine Tosylate26$217,736
Invega TrinzaPaliperidone Palmitate15$150,368
RexultiBrexpiprazole53$78,019
AristadaAripiprazole Lauroxil19$52,972
VraylarCariprazine Hcl35$45,767
Abilify MaintenaAripiprazole15$43,963
Lurasidone Hcl56$36,883
Aripiprazole127$11,784
Paliperidone ErPaliperidone28$7,634
Olanzapine220$6,710
Asenapine Maleate28$5,673
Quetiapine Fumarate200$3,822
Divalproex Sodium ErDivalproex Sodium87$3,507
Lisdexamfetamine Dimesylate12$2,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$43$217,73626 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$44$121,98268 claims
Alkermes, Inc.Aristada$196$52,97219 claims
AbbVieVraylar$47$45,76735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Tappahannock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →